Dr. Tse-Wen Chang, President
Please see Founder
Dr. Hsing-Mao Art Chu, CEO
Dr. Chu obtained his B.Sc. degree from Chang Gung University, M.Sc. degree from National Yang-Ming University, and Ph.D. degree from National Taiwan University. He started his postdoctoral research in the Institute of Biological Chemistry, Academia Sinica, and joined Dr. Chang’s laboratory in the Genomics Research Center, Academia Sinica in 2011 to study various antibody engineering methodologies and to work on CεmX and anti-CεmX antibodies.
He was invited to join Immunwork to lead the research team in 2015. He works as the CEO of T-E Meds and Vice President of R&D of Immunwork now.
Ms. Ying-Rong Lai, Vice President of Administration & Executive Assistant to Chairman
Ms. Lai obtained her Master degree in Biotechnology Management from National Taiwan University. After graduating from university in 1998, she worked in several fields, including cost control and estimation within the company, participating in biddings of multiple industries, spending several years in the high education system and engaged in trade operation and finally entered the financial system. According to her excellent management experiences in several business sectors, she was invited to work as the financial executive.
From 2004 to 2014, she was a key manager of investment at Taishin International Commercial Bank and at Yuanta Commercial Bank and won a number of service excellence awards. In 2014, she was invited by Dr. Tse-Wen Chang to join Immunwork and was responsible for assisting in establishment, administrative and financial affairs of T-E Pharma Holding. She works as the Vice President of Administration & Executive Assistant to the Chairman now.
Dr. Chi-Jiun Peng, Director, Process Development and CMC
Dr. Peng received his B.Sc. and M.Sc. degrees from Yang-Ming University in 1999 and 2001.
He then joined the Tri-Service General Hospital as a radiochemist in charge of new drug development, clinical drug production, and clinical trials. In 2013, he joined Super Laboratory Inc. as Director of Analytical Chemistry Laboratory. In 2014, he began Ph.D. studies in the Department of Chemistry, National Taiwan University doing research on glycoprotein vaccines.
After receiving Ph.D. in 2019, he joined Immunwork as a manager and then served as a director of process development of T-E Meds in 2022, responsible for CMC and manufacturing.
Dr. Jason Chi-Sheng Lu, Senior Manager, Clinical and Regulatory Strategy
Dr. Lu received his B.Sc. and M.Sc. degrees from National Tsing Hua University and Ph.D. degree from the University of Texas Health Science Center at San Antonio in the United States.
Before joining T-E Meds in 2025, Dr. Lu served as a clinical project manager at Synermore Biologicals and CMC, who was responsible for the planning and execution of clinical trials for new drug development. Before experience of clinical project management, Dr. Lu also served as a medical writer at VCRO, who was responsible for writing documents for US FDA IND and clinical trials.
In T-E Meds, Dr. Lu is mainly responsible for the submission of IND to regulatory authorities and the execution of clinical trials.
Dr. Cédric Grauffel, Manager, T-E Drug Molecular Design
Dr. Grauffel received his Ph.D. in Chemistry at the University of Strasbourg, France in 2009 and did postdoctoral research on peripheral membrane proteins and protease inhibitors in the University of Bergen, Norway in 2010-13.
He came to the Institute of Biomedical Sciences, Academia Sinica in 2013, where he worked on metal competition in proteins and aspects of drug design until 2022, when he was hired by T-E Meds as a manager in charge of the design of a new generation of T-E pharmaceuticals.
Dr. Tzu-Chen Lin, Research fellow
Dr. Lin received her Ph.D. in Chemistry and Chemical Biology from the Technical University of Dortmund, Germany, and the International Max Planck Research School for Living Matter (IMPRS-LM, former IMPRS-CMB) in 2022. She continued her post-doctoral research at the Technical University of Dortmund in 2022-2024.
During her Ph.D. studies, she focused on using chemical biology tools to modulate and investigate the functions of key epigenetic regulators. In her post-doctoral research, she led a team in developing high-throughput screening methods to identify small molecule inhibitors for an important epigenetic regulator protein.
After joining T-E Meds in 2024, Dr. Lin has been working on new drug bundle design, ADC technology platform optimization, and participated in the CMC of novel antibody-drug conjugates.